Capricor Therapeutics, Inc.
NASDAQ:CAPRBiotechnology
-$0.14 today
- Market cap
- $465.03M
- Beta
- 0.37
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$2.00
Volume 8.33M
Average 1.08M
CAPR Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Capricor Therapeutics, Inc.NASDAQ: CAPR
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures grows, but more slowly than its trailing trend
Q1 FY2026 capital expenditures of $10.75M (cash outflow) rose 842.5% year over year, behind the +958.6% change in trailing-twelve-month capital expenditures. Sequentially, it rose 109.7% from the prior quarter. Over 3 fiscal years it compounded at -4.7% a year.
Context
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +842.5% toward the trailing-twelve-month pace of +958.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (2.9M) USD
- Year-over-year change
- -88.7%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.9M) | -88.7% |
| FY2024 | 2024-12-31 | (1.54M) | +24.8% |
| FY2023 | 2023-12-31 | (2.05M) | +39.1% |
| FY2022 | 2022-12-31 | (3.36M) | -180.8% |
| FY2021 | 2021-12-31 | (1.2M) | — |
Capital Expenditures vs competitors
How CAPR compares with its peers on the latest reported figures
- CAPR's LTM Mar 2026 capital expenditures of $21.33M is the 5th largest of the 10 companies compared; the peer median is $1.19M.
- Its year-over-year change of +958.6% is the 2nd highest of 10, against a peer median of +43.1%.
- Over three fiscal years its annual growth of -4.7% compares with a peer median of -19.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $302.05M | +1172.9% | +25.3% | 29.9% | |
| LTM Sep 2026 | $71.85M | +29.1% | +36.8% | 7.5% | |
| LTM Mar 2026 | $69.14M | -54.0% | +46.8% | 3.2% | |
| LTM Jun 2026 | $21.4M | +803.5% | -14.5% | — | |
| LTM Mar 2026 | $21.33M | +958.6% | -4.7% | — | |
| LTM Mar 2026 | $1.19M | +88.9% | -27.4% | — | |
| LTM Mar 2026 | $981.99K | +43.1% | -19.2% | 1.4% | |
| LTM Mar 2026 | $139K | -75.6% | -58.7% | — | |
| LTM Sep 2026 | $126K | -72.4% | -64.1% | — | |
| LTM Mar 2026 | $59K | +101.7% | -28.8% | 1.0% | |
| Peer median (excluding CAPR) | $1.19M | +43.1% | -19.2% | 3.2% | |
Competitors are the stored peer set for CAPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (20.02M) | (29.02M) | (22.29M) | (40.47M) | (105.04M) |
| Depreciation & Amortization | 245.7K | 533.13K | 1.07M | 1.43M | 1.89M |
| Deferred Income Tax | (310.26K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.97M | 4.46M | 7.39M | 9.77M | 17.23M |
| Change in Working Capital | 182.34K | 28.75M | (11.75M) | (10.78M) | 12.2M |
| Accounts Receivables | (391.75M) | (155.83K) | (9.82M) | 3.5K | 10.31M |
| Inventory | 391.75M | 0 | 0 | 0 | 0 |
| Accounts Payables | 991.17K | 1.21M | 1.33M | 1.94M | 5.98M |
| Other Working Capital | (808.83K) | 27.7M | (3.25M) | (12.73M) | (4.09M) |
| Other Non-Cash Items | 129.73K | 196.01K | (18.24K) | 65.54K | 3.92M |
| Operating Cash Flow | (16.81M) | 4.92M | (25.6M) | (40M) | (69.81M) |
| Capital Expenditures | (1.2M) | (3.36M) | (2.05M) | (1.54M) | (2.9M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (114.22M) | (97.44M) | (208.44M) | (151.39M) |
| Sales of Investments | 0 | 82.51M | 104.6M | 93.8M | 260.6M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.2M) | (35.07M) | 5.11M | (116.18M) | 97.48M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 20.17M | 4.8M | 25.52M | 152.32M | 248.89M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 50.56K | 70.3K | 64.6K | 450.17K | 296 |
| Financing Cash Flow | 20.23M | 4.87M | 25.58M | 152.77M | 248.89M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 2.22M | (25.28M) | 5.09M | (3.41M) | 276.56M |
| Free Cash Flow | (18.01M) | 1.56M | (27.64M) | (41.53M) | (72.72M) |
Capricor Therapeutics, Inc.
NASDAQ:CAPR
Intrinsic Alpha fair value
Locked
Current Price
$8.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.